Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
Sponsor: Northwestern University
This observational or N/A phase trial investigates Renal Failure and is currently ongoing. Northwestern University leads this study, which shows 12 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Sep 2022 — Jul 2024 [monthly]
No Longer Available
-
Jan 2021 — Sep 2022 [monthly]
No Longer Available
-
Nov 2020 — Jan 2021 [monthly]
No Longer Available
▶ Show 7 earlier versions
-
Oct 2019 — Nov 2020 [monthly]
No Longer Available
-
Jan 2019 — Oct 2019 [monthly]
No Longer Available
-
Jun 2018 — Jan 2019 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Apr 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Feb 2017 — Apr 2017 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Northwestern University
- Talaris Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .